THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR").

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN.

18 February 2025

GENINCODE PLC

("GENinCode" or the "Company") (AIM: GENI.L)

Result of Retail Offer

GENinCode plc (AIM: GENI.L), a genetics company focused on the prevention of cardiovascular disease ("CVD") and the early detection of ovarian cancer, announced on 14 February 2025 the launch of a fundraising comprising a Placing and Subscription to raise a minimum of £4.0 million. The Company also announced on 14 February 2025 that it intended to carry out a separate Retail Offer via RetailBook  (the "Retail Offer"  together with the Placing and Subscription, being the "Fundraising"). The Company announced on 14 February 2025 that it had conditionally raised £4 million through the Placing and Subscription.

The Company confirms that the Retail Offer closed at 5.00 p.m. on 17 February 2025 and that it has received conditional subscriptions for 1,809,508 new Ordinary Shares at the Issue Price of 3.7 pence per share in the Retail Offer.

Following the close of the Retail Offer, the Company has conditionally raised gross proceeds of approximately £4.1 million at the Issue Price via the Fundraising. The Company will therefore allot and issue an aggregate of 109,917,616 New Ordinary Shares in connection with the Fundraising.

Each of the Retail Offer, the Placing and the Subscription is conditional upon the fundraising resolutions being duly passed without amendment at a General Meeting of the Company to be held on 3 March 2025 and Admission becoming effective at 8:00 am on or around 4 March 2025 (or such later date as the Company and its advisors may agree, but not later than 31 March 2025).

Capitalised terms used in this announcement shall, unless defined in this announcement or unless the context provides otherwise, bear the same meaning ascribed to such terms in the launch announcement.

Admission and Total Voting Rights

Application will be made to the London Stock Exchange for 109,917,616 New Ordinary Shares (comprising 88,040,541 Placing Shares, 20,067,567 Subscription Shares and 1,809,508 Retail Shares) to be admitted to trading on AIM. Admission is expected to take place and dealings in the New Ordinary Shares are expected to commence at 8.00 a.m. on or around 4 March 2025, at which time it is also expected that the New Ordinary Shares will be enabled for settlement in CREST.

Immediately following Admission, the issued share capital of the Company is expected to comprise 286,882,042 Ordinary Shares. Each Ordinary Share has one voting right and no Ordinary Shares are held in treasury. Accordingly, immediately following Admission, the total number of voting rights in the Company will be 286,882,042. From Admission, this figure may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries: 

Notes:

References to times in this Announcement are to London time unless otherwise stated.

The times and dates mentioned throughout this Announcement may be adjusted by the Company in which event the Company will make an appropriate announcement to a Regulatory Information Service giving details of any revised dates and the details of the new times and dates will be notified to London Stock Exchange plc (the "London Stock Exchange") and, where appropriate, Shareholders. Shareholders may not receive any further written communication.

IMPORTANT INFORMATION

This Announcement is not for publication or distribution, directly or indirectly, in or into the United States of America. This Announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.

This Announcement and the information contained herein, is restricted and is not for publication, release or distribution, directly or indirectly, in whole or in part, in or into Australia, Canada, the Republic of South Africa, Japan or any other jurisdiction in which such publication, release or distribution would be unlawful.  Further, this Announcement is for information purposes only and is not an offer of securities in any jurisdiction.